Global Blood Therapeutics (GBT) was downgraded to a Hold Rating at Stifel Nicolaus
Global Blood Therapeutics (GBT) was downgraded to a Hold Rating at SVB Securities
Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal
RBC Capital Downgrades Global Blood Therapeutics to Sector Perform, Raises Price Target to $68.5
Global Blood Therapeutics Price Target Raised to $68.50/Share From $66.00 by Wells Fargo
Global Blood Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo
Global Blood Therapeutics Cut to Market Perform From Outperform by SVB Leerink
Global Blood Therapeutics Price Target Announced at $68.50/Share by SVB Leerink
SVB Leerink Downgrades Global Blood Therapeutics to Market Perform, Announces $68.5 Price Target
Cowen Downgrades Global Blood Therapeutics to Market Perform From Outperform, Adjusts Price Target to $68.50 From $67
Global Blood Therapeutics Price Target Cut to $68.50/Share From $75.00 by Cantor Fitzgerald
Global Blood Therapeutics Cut to Neutral From Overweight by Cantor Fitzgerald
Global Blood Therapeutics Cut to Market Perform From Outperform by Cowen & Co.
Global Blood Therapeutics Price Target Raised to $68.50/Share From $67.00 by Cowen & Co.
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5
Global Blood Therapeutics analyst ratings
Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5
Global Blood Therapeutics Cut to Neutral From Outperform by Wedbush
Global Blood Therapeutics analyst ratings
Analysts Are Neutral on Top Healthcare Stocks: Global Blood Therapeutics (GBT), Cerevel Therapeutics Holdings (CERE)
No Data